Trials / Completed
CompletedNCT05151653
A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Intravenous Infusion or Subcutaneous Injection Doses of BI 765250 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 139 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics and pharmacodynamics following single rising doses of BI 765250.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 765250 | BI 765250 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2022-01-26
- Primary completion
- 2024-09-13
- Completion
- 2024-09-13
- First posted
- 2021-12-09
- Last updated
- 2025-01-22
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT05151653. Inclusion in this directory is not an endorsement.